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To the Editor  1 
In allergen-sensitized asthmatic individuals, allergen-specific type-2 T-helper (Th2) cells 2 
proliferate and secrete type-2 cytokines (e.g. interleukin (IL)-4, -5 and -13), driving the airway 3 
inflammatory response that gives rise to the clinical symptoms of asthma. Both early-life 4 
sensitization to aeroallergens and lower respiratory viral infections are important environmental 5 
risk factors for developing asthma. Respiratory viral infections are also the most common trigger 6 
for asthma exacerbations. Of interest, many asthma susceptibility genes are expressed in the 7 
airway epithelium[1], which forms the first continuous line of defense against inhaled 8 
environmental insults, including viruses and aeroallergens. Impaired immune regulation and 9 
failure to maintain tolerance to allergens is thought to contribute to allergic sensitization. Asthma 10 
epithelium may be deficient in its innate immune defense against virus infections, resulting in 11 
increased viral replication upon rhinovirus infection compared to non-asthma-derived epithelial  12 
cultures[2]. Furthermore, there is evidence for loss of the mucosal immune barrier in asthma, 13 
with disruption of epithelial integrity[1,3]. This may not only lead to increased permeability, but 14 
also result in the release of pro-inflammatory mediators, specifically of cytokines that drive type-15 
2 responses[3,4]. We recently observed that the ability of allergens to disrupt epithelial barrier 16 
function is related to the development of type-2-mediated inflammation in asthma[5,6]. 17 
Furthermore, we demonstrated that healthy murine lung epithelium is a potent inhibitor of T cell 18 
proliferation and that this inhibition is lost upon viral infection[7]. It is unknown if this immune 19 
regulatory effect is displayed by human epithelium and is dysregulated in asthma. We 20 
hypothesize that changes in this regulatory effect translate into aberrant regulation of T cell 21 
responses in asthma. We studied the epithelial regulation of T cell proliferation and cytokine 22 
responses upon epithelial stimulation with a viral mimic, using co-culture of human T cells and 23 
primary bronchial epithelial cells (PBECs) from healthy controls and asthma patients.  24 
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Normal PBECs obtained from Lonza (Walkersville, MD) were used, except for  the 1 
comparison between healthy and asthmatic epithelium, when PBECs derived by bronchial 2 
brushings from 5 healthy individuals and 5 patients with mild-moderate asthma, all non-smokers, 3 
were used (see fig. 1E for further characteristics). The study was approved by the Medical Ethics 4 
Committee of the UMCG. All subjects gave their written informed consent. PBECs were 5 
cultured in hormonally-supplemented bronchial epithelium growth medium (BEGM, Lonza) as 6 
described before[8-10]. PBECs were seeded in 12-well plates, grown to ~90% confluence, 7 
placed in BEGM/1% FCS overnight and pre-treated with/without 12.5µg/ml poly-(I:C) for 8 8 
hours and washed before placing in co-culture with T cells. CD4+ T cells were isolated from 10 9 
ml peripheral blood of healthy non-allergic non-smoking volunteers by Ficoll-Hypaque 10 
(Lymphoprep; Nycomed, Oslo, Norway) by density-gradient centrifugation followed by MACS 11 
sorting using CD4+ T cell Isolation Kit II (Miltenyi Biotec, San Diego, CA). T cells were seeded 12 
in duplicates at a concentration of 1.25*105/ml in 12 well plates with/without PBECs (2:1 13 
PBECs:T cells) or in the upper well of a transwell system (0.4µM pores, Corning Costar) placed 14 
above PBECs. T cells were stimulated for 96 hours in the presence/absence of PBECs in 15 
BEGM/1% FCS or in conditioned-medium from 24 hours PBEC culture. T cell proliferation was 16 
induced by α-CD3/α-CD28 immobilized to beads (Dynabeads, Invitrogen, Carlsbad, CA) and 17 
analyzed by labeling with 10 µM carboxy fluoroscein succinimidyl ester (CFSE, Life 18 
Technologies, Grand Island, NY) just prior to stimulation. CFSE dilution measurements were 19 
performed using flow cytometry (Calibur, BD) in viable CD4+/7-amino-actinomycin-Dnegative T 20 
cells. The division index was calculated at (100-Y)/Y, where Y(%) = x
0 
+ x
1
/2 + x
2
/4 + x
3
/8 + 21 
x
4
/16, x
0
= % of T cells that have not divided and x
1-4
= T cells within progressive CFSE division 22 
gates. Levels of interferon (IFN)-γ, IL-4, IL-5, IL-10 and IL-13 were analyzed in cell-free 23 
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supernatants using a multiplex ELISA kit (Millipore, Billerica, MD) and Luminex technology 1 
(Luminex Corporation, Austin, TX). 2 
We first studied the regulatory effects healthy human PBECs on T cell proliferative 3 
responses and observed an almost complete prevention of α-CD3/α-CD28-induced T cell 4 
proliferation, with suppression of all T cells (fig. 1A, B), without significant effects on T cell 5 
viability (not shown). We previously observed in mice that T cell proliferation is equally well 6 
suppressed by lung epithelial cells, whether they were cultured submerged or at the air-liquid 7 
interface (data not shown). Here, we show that the suppressive effect was still present when 8 
PBECs and T cells were separated in a transwell system, suggesting the effect does not require 9 
direct cell-cell contact (fig. 1B). In addition, the suppressive effect could be transferred by 10 
conditioned-medium derived from 24-hours culture of the epithelial cells (fig. 1C), indicating the 11 
involvement of one or several soluble mediators. Assessing cytokine production, there was no 12 
significant effect on the  type-1 cytokine IFN-γ, while healthy PBECs strongly inhibited the α-13 
CD3/α-CD28-induced secretion of the type-2 cytokines IL-4, IL-5, IL-10 and IL-13 (fig. 1D). 14 
PBECs cultured alone did not secrete detectable levels of any of these cytokines.  15 
To study whether airway epithelium in asthma is deficient in its immunosuppressive 16 
capacity, we compared the effect of PBECs from asthma patients and healthy controls (fig. 1E). 17 
Both asthma-derived and control-derived PBECS formed confluent cell monolayer, without 18 
morphological differences as observed by microscopy, and both markedly inhibited T cell 19 
proliferation (fig. 1F). However, asthma-derived PBECs were significantly less potent in doing 20 
so (fig. 1F). Furthermore, PBECs from both asthmatics and healthy controls had a similar 21 
capacity to inhibit type-2 cytokine production, as shown for IL-13 (fig. 1G), without significant 22 
differences between the subject groups. 23 
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We previously showed that regulatory effect of healthy murine epithelial cells was lost 1 
upon viral infection[7]. Respiratory RNA viruses act on Toll-like receptor (TLR)3, potentially 2 
mediating airway inflammation in virus-induced asthma exacerbations[11,12]. Therefore, we 3 
used the TLR3 agonist poly-(I:C) as a viral mimic. PBECs from controls and asthmatics were 4 
exposed to poly-(I:C) and then washed, leaving the cells viable and fully confluent, before T 5 
cells were added. Pre-treatment with poly-(I:C) strongly reduced the suppressive effect of both 6 
control and asthma-derived PBECs on T cell proliferation (fig. 1H, 1I) and attenuated the 7 
inhibitory effect of control PBECs on type-2 cytokine secretion, as shown for IL-13 (fig. 1J).  8 
Together, our data suggest that asthma and viral infection compromise the 9 
immunosuppressive capacity of airway epithelium, which may be most impaired during virus-10 
induced exacerbations of asthma, resulting in severe inflammation and a loss of asthma control. 11 
Such a major compromise of epithelial immune suppressive capacity was not found and not 12 
expected in the epithelium from stable asthma patients studied here. Viral infection of murine 13 
pulmonary epithelial cells strongly reduces their T cell suppressive capacity[7] and our current 14 
data indicate that viral infection of human airway epithelial cells will have a similar effect. Even 15 
without using live virus, the epithelial immunosuppressive effect on T cells was strongly 16 
attenuated upon exposure to the viral mimic and TLR3 agonist poly-(I:C). We speculate that 17 
such inhibition of epithelial immune regulation could enhance type-2 cytokine secretion during 18 
viral infection in early life, an important risk factor for asthma development, and during virus-19 
induced asthma exacerbations. Indeed, viral infection is accompanied by an increase in type-2 20 
cytokine secretion in mouse models[13] and in asthmatic airways, where type-2 cytokine levels 21 
relate to exacerbation severity[14].  22 
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In conclusion, we show that human bronchial epithelium exerts potent inhibitory effects 1 
on T cell proliferation and type-2 cytokine secretion. These effects are attenuated following 2 
exposure to a viral mimic, and asthma epithelium displays reduced inhibition of T cell 3 
proliferation.  Identification of the responsible mechanisms and mediator(s) involved in epithelial 4 
immune regulation may provide new targets for novel disease modifying therapeutic and 5 
preventive strategies in asthma. 6 
  7 
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Figure legend 1 
 2 
Figure 1. Primary bronchial epithelial cells (PBECs) inhibit α-CD3/α-CD28-induced T cell 3 
proliferation and associated type-2 cytokine production, an effect that is attenuated by viral 4 
stimulation and in asthma. A) Representative CFSE dilution measurement. B) Proliferation of 5 
T cells cultured in direct contact with PBECs (Lonza) compared to T cells and PBECs separated 6 
in a transwell system (n=5). C) Proliferation of T cells cultured in conditioned medium (CM) of 7 
24 hour-PBEC (Lonza) cultures (n=5). D) IFN-γ, IL-4, IL-5, IL-10 and IL-13 levels measured in 8 
cell-free supernatants by multiplex ELISA after T cell stimulation with α-CD3/α-CD28-coupled 9 
beads for 4 days in the absence/presence of PBECs ((Lonza, n=9-10).  E) Characteristics of the 10 
subjects from whom bronchial brushings were taken. Stable mild-moderate asthma patients were 11 
included based on the presence of allergy (assessed by skin test or Phadiatop) and bronchial 12 
hyperresponsiveness (assessed by PC20 AMP<16mg/ml, PC20 methacholine<8mg/ml or PC20 13 
histamine<8mg/ml), and the absence of other lung diseases and of any corticosteroid, long-acting 14 
β-agonist, and long-acting anticholinergic use for at least 4 weeks preceding the study. Medians 15 
(range) or number (%) are presented. FEV1% pred =forced expiratory volume during the first 16 
second as percentage of predicted. F) Proliferation of T cells cultured with/without PBECs from 17 
controls or asthma patients. G) IL-13 levels in cell-free supernatants of the T cells co-cultured 18 
with/without PBECs from controls or asthma patients (n=5). H) Proliferation of T cells cultured 19 
alone, with PBECs (Lonza), or with PBECs (Lonza) that were pre-treated with 12.5µg/ml poly-20 
(I:C) (n=5). I) Proliferation of T cells cultured with PBECs from asthma patients  that were pre-21 
treated with/without 12.5µg/ml poly-(I:C) (n=3). J) IL-13 levels in cell-free supernatants of the 22 
co-cultures described in H. Means ± SEM are shown. *=p<0.05, **=p<0.01, and ***=p<0.001 23 
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as analyzed by 1-way ANOVA with Bonferroni’s multiple comparison test in all graphs except 1 
for panel D and I, where an unpaired and paired Student’s t-test was used, respectively. 2 
